Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma

Corrigendum in: /10.3892/ijo.2020.5157

  • Authors:
    • Zhiyi Wang
    • Yuan Chen
    • Yanliang Lin
    • Xinxing Wang
    • Xianping Cui
    • Zhenhai Zhang
    • Guozhe Xian
    • Chengkun Qin
  • View Affiliations

  • Published online on: August 22, 2017     https://doi.org/10.3892/ijo.2017.4099
  • Pages: 1239-1248
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with broad resistance to chemotherapeutic drugs. Krüppel-like factor 4 (KLF4) is a candidate tumor suppressor in PDAC. However, the precise role of KLF4 in gemcitabine resistance of PDAC remains largely unclear. In this study, we demonstrated that gemcitabine inhibited KLF4 expression. Moreover, gemcitabine also reduced the levels of miR‑200b and miR‑183, but promoted ZEB1 expression in PDAC cells. KLF4 knockdown blocked the expression of miR‑200b and miR‑183, and inversely, KLF4 overexpression promoted the expression of miR‑200b and miR‑183, suggesting that KLF4 positively regulated the expression of miR‑200b and miR‑183. Moreover, KLF4 knockdown enhanced ZEB1 expression and gemcitabine resistance while KLF4 overexpression induced the opposite effect. ChIP assays verified that KLF4 positively regulated the expression of miR‑200b and miR‑183 by directly binding to their promoters. Then, miR‑200b and miR‑183 directly inhibited ZEB1 expression by targeting its 3'UTR region. ZEB1 knockdown attenuated gemcitabine resistance in PDAC cells. KLF4 overexpression promoted gemcitabine sensitivity of PDAC in vivo by negatively regulating ZEB1 expression. Our results revealed that novel crosstalk between KLF4 and ZEB1 regulated gemcitabine resistance in PDAC.
View Figures
View References

Related Articles

Journal Cover

October-2017
Volume 51 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang Z, Chen Y, Lin Y, Wang X, Cui X, Zhang Z, Xian G and Qin C: Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma Corrigendum in /10.3892/ijo.2020.5157. Int J Oncol 51: 1239-1248, 2017
APA
Wang, Z., Chen, Y., Lin, Y., Wang, X., Cui, X., Zhang, Z. ... Qin, C. (2017). Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma Corrigendum in /10.3892/ijo.2020.5157. International Journal of Oncology, 51, 1239-1248. https://doi.org/10.3892/ijo.2017.4099
MLA
Wang, Z., Chen, Y., Lin, Y., Wang, X., Cui, X., Zhang, Z., Xian, G., Qin, C."Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma Corrigendum in /10.3892/ijo.2020.5157". International Journal of Oncology 51.4 (2017): 1239-1248.
Chicago
Wang, Z., Chen, Y., Lin, Y., Wang, X., Cui, X., Zhang, Z., Xian, G., Qin, C."Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma Corrigendum in /10.3892/ijo.2020.5157". International Journal of Oncology 51, no. 4 (2017): 1239-1248. https://doi.org/10.3892/ijo.2017.4099